Ilomastat
Based on 63 publication(s) in Google Scholar
Ilomastat (GM6001) is a potent and broad spectrum matrix metalloprotease (MMP) inhibitor, inhibits MMPs (IC50s, 1.5 nM for MMP-1; 1.1 nM for MMP-2; 1.9 nM for MMP-3; 0.5 nM for MMP-9), with a Ki of 0.4 nM for human skin fibroblast collagenase (MMP-1).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.14%
- CAS No.: 142880-36-2
- Formule: C20H28N4O4
- Masse moléculaire:388.46
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Differentiation Inducing Compound Library
HY-L038
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Targeted Diversity Library
HY-L099
-
Rare Diseases Drug Library
HY-L102
-
Human Metabolite Library
HY-L123
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Pain-Related Compound Library
HY-L139
-
Protease Inhibitor Library
HY-L147
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Cosmetic Ingredient Compound Library
HY-L221
Publications Citing Use of MedChemExpress (MCE) Ilomastat
More- Science. 2025 Nov 6;390(6773):eadv9157. [Abstract]
- Adv Mater. 2026 Mar;38(13):e13401. [Abstract]
- Nat Biomed Eng. 2021 Sep;5(9):968-982. [Abstract]
- Bioact Mater. 2022 Feb 1:14:402-415. [Abstract]
- ACS Nano. 2024 Nov 26;18(47):32650-32671. [Abstract]
- Nat Commun. 2026 Feb 13;17(1):2737. [Abstract]
- Nat Commun. 2025 Jan 15;16(1):699. [Abstract]
- Nat Commun. 2017 Mar 7;8:14483. [Abstract]
- J Am Chem Soc. 2021 May 12;143(18):6847-6854. [Abstract]
- Adv Sci (Weinh). 2025 Oct 14:e15374. [Abstract]
- Exp Hematol Oncol. 2024 May 10;13(1):49. [Abstract]
- J Adv Res. 2024 Feb:56:125-136. [Abstract]
- Biomaterials. 2018 Aug 22;183:67-76. [Abstract]
- J Exp Med. 2023 Feb 6;220(2):e20211422. [Abstract]
- Cell Death Dis. 2025 Apr 26;16(1):346. [Abstract]
- Adv Healthc Mater. 2024 Dec 2:e2403860. [Abstract]
- Burns Trauma. 2021 Sep 17:9:tkab030. [Abstract]
- Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):11004-9. [Abstract]
- J Orthop Translat. 2021 May 24:29:89-99. [Abstract]
- Cell Syst. 2025 Aug 20;16(8):101353. [Abstract]
- Biomed Pharmacother. 2024 Jun 27:177:117033. [Abstract]
- Chin Med J (Engl). 2025 Jun 5;138(11):1367-1378. [Abstract]
- Int J Nanomedicine. 2018 Aug 13:13:4641-4659. [Abstract]
- Int J Nanomedicine. 2016 Apr 22:11:1643-61. [Abstract]
- JCI Insight. 2026 Jan 22;11(5):e195176. [Abstract]
- Ecotoxicol Environ Saf. 2023 Jan 15:250:114497. [Abstract]
- Int J Mol Med. 2020 Apr;45(4):1017-1026. [Abstract]
- Mech Ageing Dev. 2023 Apr:211:111779. [Abstract]
- Int Immunopharmacol. 2025 Apr 16:152:114405. [Abstract]
- Bioorg Chem. 2025 Jun 1:159:108393. [Abstract]
- Int Immunopharmacol. 2024 Jan 5:126:111215. [Abstract]
- Am J Physiol Cell Physiol. 2017 Dec 1;313(6):C632-C643. [Abstract]
- J Cell Mol Med. 2026 Mar;30(5):e71076. [Abstract]
- iScience. 2025 Dec 6;29(1):114358. [Abstract]
- iScience. 2025 Jul 31;28(9):113255. [Abstract]
- J Biol Chem. 2026 Jan 20:111182. [Abstract]
- Biomedicines. 2026 Jan 27;14(2):286. [Abstract]
- Sci Rep. 2025 May 6;15(1):15762. [Abstract]
- J Biol Chem. 2023 Oct;299(10):105211. [Abstract]
- Sci Rep. 2019 Feb 20;9(1):2385. [Abstract]
- J Periodontol. 2021 Nov;92(11):128-138. [Abstract]
- BMC Genomics. 2020 Feb 19;21(1):171. [Abstract]
- Biometals. 2023 Jun;36(3):629-638. [Abstract]
- Biochim Biophys Acta Mol Cell Biol Lipids. 2025 Apr 26:159618. [Abstract]
- Endocrine. 2021 May;72(2):529-538. [Abstract]
- Biochem Biophys Res Commun. 2018 Mar 25;498(1):125-131. [Abstract]
- ChemistrySelect. 2023 Jan 12.
- J Burn Care Res. 2023 Nov 2;44(6):1371-1381. [Abstract]
- bioRxiv. 2026 Jun 3:2026.06.01.728985. [Abstract]
- bioRxiv. 2026 May 20:2026.05.18.725979. [Abstract]
- Hlife. 2026 Mar 11.
- Saarland University. 2025.
- University of Cambridge. 2023 Dec 13.
- Phytomedicine Plus. 2023 May 4, 100456.
- bioRxiv. 2023 Jan 23:2023.01.23.523684. [Abstract]
- Research Square Print. September 14th, 2022.
- Oxid Med Cell Longev. 2021 Nov 26:2021:5710440. [Abstract]
- bioRxiv. 2021 Jan 5.
- Patent. US20210002378A1.
- Research Square Preprint. 2019 Dec.
- ACS Comb Sci. 2019 Dec 9;21(12):805-816. [Abstract]
- Journal of Nutritional Oncology. 2019 4(4):187-192.
- Queen’s University. 2019 Sep.
Customer Validation & Images
-
IF
-
WB
-
Cell Proliferation/Viability Assay
Activité biologique
|
MMP-9 0.5 nM (IC50) |
MMP-2 1.1 nM (IC50) |
MMP-1 1.5 nM (IC50) |
MMP-3 1.9 nM (IC50) |
Fibroblast collagenase 0.4 nM (Ki, Human skin) |
Thermolysin 20 nM (Ki) |
Eastase 20 nM (Ki) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
480 nM
Compound: GM6001
|
Inhibition of human recombinant ADAMTS4 expressed in HEk293 cells using FAM-AEwLQGRPISIAK-TAMRA as substrate measured for 15 mins by fluorometric analysis
Inhibition of human recombinant ADAMTS4 expressed in HEk293 cells using FAM-AEwLQGRPISIAK-TAMRA as substrate measured for 15 mins by fluorometric analysis
|
[PMID: 23376997] |
| HEK293 | IC50 |
500 nM
Compound: GM6001
|
Inhibition of human recombinant ADAMTS5 expressed in HEK293 cells using Abz-TESEwSRGAIY-Dpa-KK as substrate measured for 2 hrs by fluorometric analysis
Inhibition of human recombinant ADAMTS5 expressed in HEK293 cells using Abz-TESEwSRGAIY-Dpa-KK as substrate measured for 2 hrs by fluorometric analysis
|
[PMID: 23376997] |
Ilomastat (GM6001) inhibits human skin fibroblast collagenase, thermolysin and elastase with Kis?of 0.4 nM, 20 nM, 20 nM, resepctively[1].?Ilomastat (0.1-10 nM) inhibits gelatinase A and gelatinase B produced by T-cells. Ilomastat inhibits T-cell homing[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 142880-36-2
-
Appearance Solid
-
Masse moléculaire 388.46
-
Formule C20H28N4O4
-
Color White to yellow
-
SMILES
O=C(N[C@@H](CC1=CNC2=C1C=CC=C2)C(NC)=O)[C@H](CC(C)C)CC(NO)=O
-
Synonyms
GM6001; Galardin
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (63)
-
Journal Impact Factor
-
Most Recent
-
Science
Preventing hypocontractility-induced fibroblast expansion alleviates dilated cardiomyopathy. [Abstract]2025 Nov 6;390(6773):eadv9157. PMID: 40934290 -
Adv Mater
Engineered Perfusable Hepatic Fibrosis Model via Embedded Sacrificial Bioprinting Recapitulates Stiffness-Driven Fibrogenesis. [Abstract]2026 Mar;38(13):e13401. PMID: 41568614 -
Nat Biomed Eng
Reduction of choroidal neovascularization via cleavable VEGF antibodies conjugated to exosomes derived from regulatory T cells. [Abstract]2021 Sep;5(9):968-982. PMID: 34312509 -
Bioact Mater
Verteporfin-mediated on/off photoswitching functions synergistically to treat choroidal vascular diseases. [Abstract]2022 Feb 1:14:402-415. PMID: 35386820 -
ACS Nano
Peroxynitrite-Free Nitric Oxide-Embedded Nanoparticles Maintain Nitric Oxide Homeostasis for Effective Revascularization of Myocardial Infarcts. [Abstract]2024 Nov 26;18(47):32650-32671. PMID: 39545833 -
Nat Commun
Engineered exosome nanovesicles for delivery of antibodies to treat inflammatory bowel disease. [Abstract]2026 Feb 13;17(1):2737. PMID: 41688436 -
Nat Commun
Microglial NLRP3-gasdermin D activation impairs blood-brain barrier integrity through interleukin-1β-independent neutrophil chemotaxis upon peripheral inflammation in mice. [Abstract]2025 Jan 15;16(1):699. PMID: 39814731 -
Nat Commun
Loss of ERα induces amoeboid-like migration of breast cancer cells by downregulating vinculin. [Abstract]2017 Mar 7;8:14483. PMID: 28266545
Ilomastat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2017 Mar 7;8:14483. [Abstract]
A transwell assay is performed in MDA-MB-231 cells, GM6001-treated MDA-MB-231 cells or GM6001-treated and CRISPR/Cas9-mediated VCL deleted MDA-MB-231 cells
-
J Am Chem Soc
Truncated Actin-Targeting Macrolide Derivative Blocks Cancer Cell Motility and Invasion of Extracellular Matrix. [Abstract]2021 May 12;143(18):6847-6854. PMID: 33938740 -
Adv Sci (Weinh)
2025 Oct 14:e15374. PMID: 41085070 -
Exp Hematol Oncol
Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis. [Abstract]2024 May 10;13(1):49. PMID: 38730491 -
J Adv Res
Matrix metalloproteinase-9 inhibition prevents aquaporin-4 depolarization-mediated glymphatic dysfunction in Parkinson's disease. [Abstract]2024 Feb:56:125-136. PMID: 36940850 -
Biomaterials
Visualizing collagen proteolysis by peptide hybridization: From 3D cell culture to in vivo imaging. [Abstract]2018 Aug 22;183:67-76. PMID: 30149231 -
J Exp Med
Activating NO-sGC crosstalk in the mouse vascular niche promotes vascular integrity and mitigates acute lung injury. [Abstract]2023 Feb 6;220(2):e20211422. PMID: 36350314 -
Cell Death Dis
MMP1-induced NF-κB activation promotes epithelial-mesenchymal transition and sacituzumab govitecan resistance in hormone receptor-positive breast cancer. [Abstract]2025 Apr 26;16(1):346. PMID: 40287412 -
Adv Healthc Mater
2024 Dec 2:e2403860. PMID: 39623803 -
Burns Trauma
Neutrophil-derived heparin binding protein triggers vascular leakage and synergizes with myeloperoxidase at the early stage of severe burns (With video). [Abstract]2021 Sep 17:9:tkab030. PMID: 34646891 -
Proc Natl Acad Sci U S A
E4F1-mediated control of pyruvate dehydrogenase activity is essential for skin homeostasis. [Abstract]2016 Sep 27;113(39):11004-9. PMID: 27621431 -
J Orthop Translat
Andrographolide attenuates synovial inflammation of osteoarthritis by interacting with tumor necrosis factor receptor 2 trafficking in a rat model. [Abstract]2021 May 24:29:89-99. PMID: 34094861 -
Cell Syst
Tumor-adipose assembloids reveal cell-fate-transition-triggered multistage collective invasions. [Abstract]2025 Aug 20;16(8):101353. PMID: 40782801 -
Biomed Pharmacother
2024 Jun 27:177:117033. PMID: 38941889 -
Chin Med J (Engl)
Involvement of interferon γ-producing mast cells in immune responses against melanocytes in vitiligo requires MrgX2 activation. [Abstract]2025 Jun 5;138(11):1367-1378. PMID: 39344472 -
Int J Nanomedicine
Matrix metalloproteinase 2/9-triggered-release micelles for inhaled drug delivery to treat lung cancer: preparation and in vitro/in vivo studies. [Abstract]2018 Aug 13:13:4641-4659. PMID: 30147314
Ilomastat purchased from MedChemExpress. Usage Cited in: Int J Nanomedicine. 2018 Aug 13:13:4641-4659. [Abstract]
Cellular uptake of P123-Cou6 and PG-SG-Cou6 micelles in MCF7 and MCF7/ADR cells in the presence of GM6001.
-
Int J Nanomedicine
Matrix metalloproteinases-2/9-sensitive peptide-conjugated polymer micelles for site-specific release of drugs and enhancing tumor accumulation: preparation and in vitro and in vivo evaluation. [Abstract]2016 Apr 22:11:1643-61. PMID: 27217744 -
JCI Insight
LYVE1 ectodomain shedding blunts lymphatic transmigration and clearance of macrophages during kidney injury. [Abstract]2026 Jan 22;11(5):e195176. PMID: 41587141 -
Ecotoxicol Environ Saf
Embryonic 6:2 FTOH exposure causes reproductive toxicity by disrupting the formation of the blood-testis barrier in offspring mice. [Abstract]2023 Jan 15:250:114497. PMID: 36608565 -
Int J Mol Med
Role of the p53‑TRPM1/miR‑211‑MMP9 axis in UVB‑induced human melanocyte migration and its potential in repigmentation. [Abstract]2020 Apr;45(4):1017-1026. PMID: 31985026 -
Mech Ageing Dev
Acceleration of melanocyte senescence by the proinflammatory cytokines IFNγ and TNFα impairs the repigmentation response of vitiligo patients to narrowband ultraviolet B (NBUVB) phototherapy. [Abstract]2023 Apr:211:111779. PMID: 36731753 -
Int Immunopharmacol
Jatrorrhizine retard obesity by modulating transcription factor c-Jun/c-Fos to downregulate Mmp12-mediated inflammation. [Abstract]2025 Apr 16:152:114405. PMID: 40086054 -
Bioorg Chem
A novel MMP-9 inhibitor exhibits selective inhibition in non-small-cell lung cancer harboring EGFR T790M mutation by blocking EGFR/STAT3 signaling pathway. [Abstract]2025 Jun 1:159:108393. PMID: 40121769 -
Int Immunopharmacol
MMP-9 inhibition alleviates postoperative cognitive dysfunction by improving glymphatic function via regulating AQP4 polarity. [Abstract]2024 Jan 5:126:111215. PMID: 38000234 -
Am J Physiol Cell Physiol
(Pro)renin receptor mediates albumin-induced cellular responses: role of site-1 protease-derived soluble (pro)renin receptor in renal epithelial cells. [Abstract]2017 Dec 1;313(6):C632-C643. PMID: 28903918 -
J Cell Mol Med
Alpha-Fetoprotein Stimulates Cleavage of Membranal MICA/B on Liver Cancer Cell Lead to Escape Immune Surveillance of Natural Killer Cells. [Abstract]2026 Mar;30(5):e71076. PMID: 41749070 -
iScience
Obesity-induced pyroptotic adipocyte death leads to TREM2-dependent macrophage dysfunction and adipose tissue inflammation. [Abstract]2025 Dec 6;29(1):114358. PMID: 41509917 -
iScience
Tissue stiffness controls neuroblast migratory behavior and reprogramming during myelin repair. [Abstract]2025 Jul 31;28(9):113255. PMID: 40837231 -
J Biol Chem
Andrographolide targets syndecan4 to impair its interaction with syntenin and inhibits the biogenesis of small extracellular vesicles. [Abstract]2026 Jan 20:111182. PMID: 41570990 -
Biomedicines
Environmental Lead Promotes Breast Cancer Migration and Invasion via the AKR1C3-NF-κB-MMP Axis. [Abstract]2026 Jan 27;14(2):286. PMID: 41751184 -
Sci Rep
Pharmacological alternatives to oxytetracycline as potential treatment of flexural limb deformities in foals: a preliminary in vitro cell viability and proliferation study. [Abstract]2025 May 6;15(1):15762. PMID: 40328831 -
J Biol Chem
Golgi α-Mannosidases Regulate Cell Surface N-Glycan Type and Ectodomain Shedding of the Transmembrane Protease Corin. [Abstract]2023 Oct;299(10):105211. PMID: 37660903 -
Sci Rep
A PKA/cdc42 Signaling Axis Restricts Angiogenic Sprouting by Regulating Podosome Rosette Biogenesis and Matrix Remodeling. [Abstract]2019 Feb 20;9(1):2385. PMID: 30787359 -
J Periodontol
2021 Nov;92(11):128-138. PMID: 34231875 -
BMC Genomics
2020 Feb 19;21(1):171. PMID: 32075574 -
Biometals
Albumin fusion with human lactoferrin shows enhanced inhibition of cancer cell migration. [Abstract]2023 Jun;36(3):629-638. PMID: 36167912 -
Biochim Biophys Acta Mol Cell Biol Lipids
2025 Apr 26:159618. PMID: 40294697 -
Endocrine
125I-Angiotensin 1-7 binds to a different site than angiotensin 1-7 in tissue membrane preparations. [Abstract]2021 May;72(2):529-538. PMID: 33415576 -
Biochem Biophys Res Commun
MMP9 is involved in HO-1-mediated upregulation of apical junctional complex in Caco-2 cells under oxygen-glucose deprivation. [Abstract]2018 Mar 25;498(1):125-131. PMID: 29425821
Ilomastat purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2018 Mar 25;498(1):125-131. [Abstract]
Cell lysates are immunoblotted with antibodies against Claudin-4, E-cadherin, β-catenin, MMP9 and GAPDH.
-
-
J Burn Care Res
Downregulation of RUNX1-activated osteopontin facilitates burn wound healing by activating the MAPK pathways. [Abstract]2023 Nov 2;44(6):1371-1381. PMID: 36913234 -
bioRxiv
ProNotch converts extracellular protease activity into programmable transcriptional outputs. [Abstract]2026 Jun 3:2026.06.01.728985. PMID: 42282718 -
bioRxiv
Nuclear SUN2 coordinates endothelial cell-matrix interactions to regulate blood vessel homeostasis and barrier function. [Abstract]2026 May 20:2026.05.18.725979. PMID: 42239109 -
-
-
-
-
bioRxiv
2023 Jan 23:2023.01.23.523684. PMID: 36747691 -
-
Oxid Med Cell Longev
Advanced Oxidation Protein Product Promotes Oxidative Accentuation in Renal Epithelial Cells via the Soluble (Pro)renin Receptor-Mediated Intrarenal Renin-Angiotensin System and Nox4-H2O2 Signaling. [Abstract]2021 Nov 26:2021:5710440. PMID: 34873430 -
-
-
-
ACS Comb Sci
Benzimidazolyl-pyrazolo[3,4- b]pyridinones, Selective Inhibitors of MOLT-4 Leukemia Cell Growth and Sea Urchin Embryo Spiculogenesis: Target Quest. [Abstract]2019 Dec 9;21(12):805-816. PMID: 31689077 -
-
Solvant et solubilité
DMSO : 50 mg/mL (128.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
To assess the effects of MMP inhibition, animals are given daily injections of either vehicle (“placebo group”) or Ilomastat (GM6001) (100 mg/kg per day as subcutaneous suspension), beginning one day before the second injury until seven days after the procedure. Ilomastat (GM6001) is a nonspecific hydroxamic acid-based MMPI with potent inhibitory activity against collagenase, gelatinases and stromelysin. Animals are euthanized at either 1 week or 10 weeks after the second injury.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Grobelny D, et al. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry. 1992 Aug 11;31(31):7152-4. [Content Brief]
[2]. Schultz GS, et al. Treatment of alkali-injured rabbit corneas with a synthetic inhibitor of matrix metalloproteinases. Invest Ophthalmol Vis Sci. 1992 Nov;33(12):3325-31. [Content Brief]
[3]. Li C, et al. Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor. J Am Coll Cardiol. 2002 Jun 5;39(11):1852-8. [Content Brief]
[4]. Leppert D, et al. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol. 1995 May 1;154(9):4379-89. [Content Brief]
[5]. Yamamoto M, et al. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket. J Med Chem. 1998 Apr 9;41(8):1209-17. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5743 mL | 12.8713 mL | 25.7427 mL | 64.3567 mL |
| 5 mM | 0.5149 mL | 2.5743 mL | 5.1485 mL | 12.8713 mL | |
| 10 mM | 0.2574 mL | 1.2871 mL | 2.5743 mL | 6.4357 mL | |
| 15 mM | 0.1716 mL | 0.8581 mL | 1.7162 mL | 4.2904 mL | |
| 20 mM | 0.1287 mL | 0.6436 mL | 1.2871 mL | 3.2178 mL | |
| 25 mM | 0.1030 mL | 0.5149 mL | 1.0297 mL | 2.5743 mL | |
| 30 mM | 0.0858 mL | 0.4290 mL | 0.8581 mL | 2.1452 mL | |
| 40 mM | 0.0644 mL | 0.3218 mL | 0.6436 mL | 1.6089 mL | |
| 50 mM | 0.0515 mL | 0.2574 mL | 0.5149 mL | 1.2871 mL | |
| 60 mM | 0.0429 mL | 0.2145 mL | 0.4290 mL | 1.0726 mL | |
| 80 mM | 0.0322 mL | 0.1609 mL | 0.3218 mL | 0.8045 mL | |
| 100 mM | 0.0257 mL | 0.1287 mL | 0.2574 mL | 0.6436 mL |
Powered by Bioz